Upgrade to SI Premium - Free Trial

Keros Therapeutics (KROS)

11.35 +0.17 (1.52%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/11/26)

Latest Headlines

Keros Therapeutics to receive $20M milestone from Takeda September 29, 2026 8:02 AM - StreetInsider Form 8-K Keros Therapeutics, Inc. For: Sep 29 September 29, 2026 8:01 AM - SEC Filing Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda September 29, 2026 8:01 AM - Globe NewsWire Form 8-K Keros Therapeutics, Inc. For: Sep 28 September 28, 2026 8:01 AM - SEC Filing Keros Therapeutics doses first patient in Phase 2 DMD rinvatercept trial September 28, 2026 8:00 AM - StreetInsider Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD September 28, 2026 8:00 AM - Globe NewsWire Form EFFECT Keros Therapeutics, Inc. September 17, 2026 6:03 AM - SEC Filing Form DEL AM Keros Therapeutics, Inc. September 11, 2026 4:02 PM - SEC Filing Keros Therapeutics (KROS) files $350M mixed shelf September 10, 2026 4:04 PM - StreetInsider Form S-3 Keros Therapeutics, Inc. September 10, 2026 4:03 PM - SEC Filing Form 4 Keros Therapeutics, Inc. For: Aug 17 Filed by: BIENAIME JEAN JACQUES August 27, 2026 7:02 PM - SEC Filing Form 4 Keros Therapeutics, Inc. For: Aug 18 Filed by: Tanini Annita August 20, 2026 4:10 PM - SEC Filing Form 4 Keros Therapeutics, Inc. For: Aug 18 Filed by: Lerner Lorena Raquel August 20, 2026 4:10 PM - SEC Filing Form 4 Keros Therapeutics, Inc. For: Aug 18 Filed by: Cho Esther August 20, 2026 4:10 PM - SEC Filing Form 4 Keros Therapeutics, Inc. For: Aug 18 Filed by: Newton Charles W. August 20, 2026 4:10 PM - SEC Filing Form 4 Keros Therapeutics, Inc. For: Aug 17 Filed by: BIENAIME JEAN JACQUES August 19, 2026 4:10 PM - SEC Filing Form 144 Keros Therapeutics, Inc. Filed by: Newton Charles W. August 18, 2026 4:11 PM - SEC Filing Form 3 Keros Therapeutics, Inc. For: Aug 04 Filed by: Tanini Annita August 13, 2026 4:14 PM - SEC Filing Keros Therapeutics (KROS) PT Lowered to $18 at Wells Fargo August 4, 2026 8:06 AM - StreetInsider H.C. Wainwright Reiterates Buy Rating on Keros Therapeutics (KROS) August 4, 2026 6:53 AM - StreetInsider Keros Therapeutics (KROS) Misses Q2 EPS by 5c August 3, 2026 4:47 PM - StreetInsider Form 8-K Keros Therapeutics, Inc. For: Aug 03 August 3, 2026 4:08 PM - SEC Filing Form 10-Q Keros Therapeutics, Inc. For: Jun 30 August 3, 2026 4:03 PM - SEC Filing Form 8-K Keros Therapeutics, Inc. For: Aug 03 August 3, 2026 4:02 PM - SEC Filing Keros Therapeutics Reports Second Quarter 2026 Financial Results August 3, 2026 4:01 PM - Globe NewsWire Form 8-K Keros Therapeutics, Inc. For: Jul 30 July 30, 2026 4:02 PM - SEC Filing Keros Therapeutics to receive $20M milestone from Takeda July 30, 2026 4:01 PM - StreetInsider Keros Therapeutics to Receive Development Milestone Payment from Partner Takeda July 30, 2026 4:01 PM - Globe NewsWire Form SCHEDULE 13G/A Keros Therapeutics, Inc. Filed by: BlackRock, Inc. July 29, 2026 3:22 PM - SEC Filing Full Article List